Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.

International journal of clinical oncology - 1 Aug 2007

Jiko Mari, Yano Ikuko, Sato Eriko, Takahashi Kazushige, Motohashi Hideyuki, Masuda Satohiro, Okuda Masahiro, Ito Noriyuki, Nakamura Eijiro, Segawa Takehiko, Kamoto Toshiyuki, Ogawa Osamu, Inui Ken-Ichi

Abstract excerpt

BACKGROUND: We investigated the pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine in patients with urogenital cancer to clarify the significance of monitoring of the serum concentration of paclitaxel. METHODS: Paclitaxel was administered at 175 mg/m(2) or 150 mg/...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Deoxycytidine

Share to Gemcitabine

Share to Metabolic Clearance Rate

Share to Paclitaxel

Share to Prostate-Specific Antigen

Source

Identifiers

PMID: 17701008
DOI: 10.1007/s10147-007-0681-y

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-17701008-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.PMID 17701008Read ↗

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.Semantic proximity Read ↗

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.Semantic proximity Read ↗

Individualized pharmacotherapy with paclitaxel.Semantic proximity Read ↗

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.Semantic proximity Read ↗

Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.Semantic proximity Read ↗

Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.Semantic proximity Read ↗

Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.Semantic proximity Read ↗

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.Semantic proximity Read ↗

Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphismsSemantic proximity Read ↗

Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel.Semantic proximity Read ↗

Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.Semantic proximity Read ↗

Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.